Volume 15, Number 6—June 2009
Letter
Extensively Drug-Resistant Acinetobacter baumannii
Table
Drugs | MIC, μg/mL | Interpretation |
---|---|---|
Carbapanems | ||
Imipenem | >32 | Resistant |
Meropenem |
>32 |
Resistant |
Penicillins | ||
Ampicillin/sulbactam | 32 | Resistant |
Piperacillin/tazobactam |
>256 |
Resistant |
Cephalosporins | ||
Ceftazidime | 48 | Resistant |
Cefepime |
16 |
Intermediate |
Aminoglycosides | ||
Gentamicin | >256 | Resistant |
Tobramycin | >256 | Resistant |
Amikacin |
>256 |
Resistant |
Others | ||
Ciprofloxacin | >32 | Resistant |
Tigecycline | 2 | Intermediate |
Colistin | >1,024 | Resistant |
*Susceptibility testing was performed by using the Etest (AB Biodisk, Solna, Sweden), except for colistin, for which the standard agar dilution method was used. Interpretation was according to breakpoints provided by the Clinical and Laboratory Standards Institute (CLSI; Wayne, PA, USA). No tigecycline breakpoints for Acinetobacter spp. are provided by the CLSI, the European Committee on Antimicrobial Susceptibility Testing (Basel, Switzerland), or the US Food and Drug Administration (Silver Spring, MD, USA). Breakpoints of the British Society for Antimicrobial Chemotherapy (Birmingham, UK) are indicated for tigecycline.
Page created: December 08, 2010
Page updated: December 08, 2010
Page reviewed: December 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.